Ultrasensitive Immunoassay Services

Ultrasensitive NF-L assay; a promising blood-based biomarker for neurodegenerative diseases

Many high profile studies have been published in the last year demonstrating the utility of this blood-based assay for Alzheimer’s disease, 1,2 frontotemporal dementia, 3,4 multiple sclerosis, 5,6,7 traumatic brain injury, 8,9 Huntington’s 10 and Parkinson’s  disease.11

RBM’s Ultrasensitve Simoa™ NF-L Immunoassay
Plasma/Serum LLOQ 1.00 pg/mL

The potential for Neurofilament light chain (NF-L) as a blood-based biomarker for neurodegenerative disease is growing rapidly because of two breakthroughs: 12, 13

  1. Application of the SimoaTM ultrasensitive immunoassay platform to accurately measure blood levels of NF-L 14, 15
  2. A high correlation of NF-L levels between cerebral spinal fluid and serum or plasma 16, 17, 18

Testing of ultrasensitive NF-L immunoassay with native NF-L controls is performed in our CLIA certified laboratory.

Measure plasma and serum protein biomarkers at fg/mL concentrations with RBM’s ultrasensitive NF-L testing services.

  1. Mattsson N et al. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2017 May 1;74(5):557–566.
  2. Zhou W et al. Plasma neurofilament light chain levels in Alzheimer’s disease. Neurosci Lett. 2017 May 22;650:60-64. Epub 2017 Apr 18.
  3. Rohrer JD et al.  Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016 Sep 27; 87(13) 1329-1336. Epub 2016 Aug 31.
  4. Meeter LH et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016 Aug; 3(8): 623-636. Epub 2016 Jul 1.
  5. Disanto G et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017 Jun;81(6):857-870.
  6. Piehl F et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler. 2017 Jun 1: doi: 10.1177/1352458517715132.[Epub ahead of print].
  7. Bergman J et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol Neuroimmunol Neuroinflamm. 2016 Oct; 3(5): e271.Epub 2016 Aug 2.
  8. Shahim P et al. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology. 2017 May 9;88(19):1788-1794. Epub 2017 April 12.
  9. Shahim P et al. Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep. 2016; 6:36791.
  10. Byrne LM et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurol. 2017 Aug;16(8):601-609. Epub 2017 Jun 7.
  11. Hansson O et al. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017 Mar 7;88(10):930-937. Epub 2017 Feb 8.
  12. Oliver JM et al. Serum Neurofilament Light in American Football Athletes over the Course of a Season. J Neurotrauma. 2016 Oct 1; 33(19):1784-1789. Epub 2016 Mar 16.
  13. Rojas JC et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016 Mar; 3(3): 216–225. Epub 2016 Feb 1.
  14. Ljungqvist J et al. Serum Neurofilament Light Protein as a Marker for Diffuse Axonal Injury: Results from a Case Series Study. Journal of Neurotrauma. Mar 2017, 34(5): 1124 1127. Epub 2016 Oct 13.
  15. Kuhle J et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016 Oct 1; 54(10):1655-61.
  16. Kovacs GG et al. Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol. 2017 Aug 16. doi: 10.1111/ene.13389. [Epub ahead of print]
  17. Steinacker P et al. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep. 2016 Dec 8;6:38737.
  18. Gisslén M et al. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine. 2016 Jan 2; (3):135-40. Epub 2015 Nov.